Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical photodynamic therapy with fractionated 5-ALA 20% versus two-stage Metvix (MAL) for superficial basal cell carcinoma
2011-005809-77Phase 4Active
- Sponsor
- Maastricht University Medical Center+
- Start
- Dec 2011
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methyl aminolevulinate, 5-aminolevulinic acid in basal cell carcinoma (BCC), sponsored by Maastricht University Medical Center+. Started Dec 2011; status: active.
02
Drugs
methyl aminolevulinate5-aminolevulinic acid
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2011-005809-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005809-77.